Kim et al. found that BRCA2 mutant-lung cancer organoids showed a good response to olaparib whereas EGFR mutant and EGFR-mutant/MET-amplified organoids showed better response to erlotinib and crizotinib, respectively [62]. The gene discussed is MET; the disease is lung cancer.